Slides
Page 1
Q2 & H1 FY25 Earnings Presentation, November 07, 2024 Q2 & H1 FY27 Earnings Presentation November 3, 2026
Page 2
2 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
Page 3
Strategic Expansion Q2 FY27 & H1 FY27 Performance Snapshot
Page 4
4 Q2 FY27 Performance Snapshot Financial Performance Key Metrics INR 2,554 Mn Revenue from Operations INR 1,128 Mn | 44.1% EBITDA | EBITDA Margin % INR 595 Mn | 23.3% PAT | PAT Margin % Geographical Contribution 1.37 Mn Footfall 168 Centres 92% B2C Revenue % 4.98 Mn Tests Wellness Share%YOY Growth % 67%20% 5% 5% 3% Hyderabad RoAPT Pune West Bengal Others 14.5% Welness Share % Revenue Growth % Test Volume Growth % Footfall Growth % 16.5% 14.5%26.7% 37.4%37.8% EBITDA Growth % PAT Growth %
Page 5
5 H1 FY27 Performance Snapshot Financial Performance Key Metrics INR 4,864 Mn Revenue from Operations INR 2,113 Mn | 43.4% EBITDA | EBITDA Margin % INR 1,126 Mn | 23.1% PAT | PAT Margin % Geographical Contribution 2.61 Mn Footfall 168 Centres 92% B2C Revenue % 9.57 Mn Tests Wellness Share%YOY Growth % 67%20% 6% 4% 3% Hyderabad RoAPT Pune West Bengal Others 14.6% Welness Share % Revenue Growth % Test Volume Growth % Footfall Growth % 16.5% 13.7%24.8% 37.5%36.0% EBITDA Growth % PAT Growth %
Page 6
6 Management Commentary Commenting on the Q2 FY27 & H1 FY27 results and future business outlook, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said: I am pleased to share that we have sustained our strong growth momentum during Q2 FY27, delivering 26.7% year-on- year revenue growth, supported by 16.5% volume growth. Our existing centres grew by approximately 20%, while newer centres continued to ramp up well. Our core markets maintained strong momentum, while Pune has been witnessing a meaningful turnaround with consistent double-digit growth since few quarters. We continue to see encouraging momentum in West Bengal, as our brand awareness strengthens. We are particularly pleased with the response in Tier-II markets such as Krishnanagar and Diamond Harbour. On the expansion front, we have commissioned 2 hubs and 7 spokes so far during FY27. Looking ahead, we expect to commission another 3 hubs & 7 spokes in H2 FY27, followed by 3 additional hubs in Q1 FY28, further strengthening our network and expanding our presence across key markets. During the quarter, we entered into Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam. This marks our entry into the North-East region and is an important step towards expanding our geographical presence beyond our existing markets. We believe this acquisition provides us with a strong platform to establish our presence in Guwahati and gradually explore further growth opportunities across the North-East, leveraging our expertise in integrated diagnostics and operational excellence. We remain committed to strengthening our presence across key markets, investing in advanced technology and delivering high-quality diagnostic services to support sustainable long-term growth. “ ”
Page 7
7 Key Financial Highlights Revenue from Operations 2,016 2,310 2,554 3,896 4,864 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 818 985 1,128 1,554 2,113 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 40.6% 42.7% EBITDA & EBITDA Margin % 433 531 595 819 1,126 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 PAT & PAT Margin % Revenue Mix Key Financials Radiology vs. Pathology Breakdown % 38% 37% 37% 38% 37% 62% 63% 63% 62% 63% Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Radiology Pathology Wellness share %B2C Revenue % 92% 92% 92% 92% 92% Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 14.4% 14.8% 14.5% 14.3% 14.6% Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 44.1% 39.9% 43.4% 21.5% 23.0% 23.3% 21.0% 23.1% (INR Mn)
Page 8
8 Key Operational Highlights Tests Performed (# in Mn) 4.28 4.59 4.98 8.22 9.57 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Footfalls (# in Mn) 1.20 1.24 1.37 2.30 2.61 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Tests / Footfalls (#) 3.57 3.70 3.64 3.58 3.67 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Revenue per Test (INR) 471 503 513 474 508 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Revenue per Footfall (INR) 1,685 1,860 1,865 1,696 1,862 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27
Page 9
9 Consolidated Profit & Loss Statement *Not annualized (INR Mn) Particulars Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q H1 FY27 H1 FY26 Y-o-Y Revenue from operations 2,553.9 2,015.6 26.7% 2,309.8 10.6% 4,863.7 3,896.1 24.8% Cost of materials consumed 282.6 243.2 16.2% 256.0 10.4% 538.6 457.3 17.8% Gross Profit 2,271.2 1,772.4 28.1% 2,053.9 10.6% 4,325.1 3,438.8 25.8% Gross Profit (%) 88.9% 87.9% 100 bps 88.9% 1 bps 88.9% 88.3% 66 bps Employee benefits expense 383.5 322.6 18.9% 374.8 2.3% 758.2 638.7 18.7% Other expenses 760.3 631.6 20.4% 693.7 9.6% 1,454.0 1,246.6 16.6% EBITDA 1,127.5 818.3 37.8% 985.4 14.4% 2,112.9 1,553.6 36.0% EBITDA Margin (%) 44.1% 40.6% 355 bps 42.7% 149 bps 43.4% 39.9% 357 bps Other income 49.5 62.5 -20.8% 85.3 -42.0% 134.8 133.0 1.4% Depreciation and amortization expense 269.0 222.7 20.8% 251.2 7.1% 520.2 431.6 20.5% EBIT 908.0 658.1 38.0% 819.5 10.8% 1,727.4 1,255.0 37.6% Finance costs 113.8 78.3 45.4% 110.0 3.4% 223.8 153.1 46.2% Profit before Exceptional Items & Tax 794.2 579.8 37.0% 709.4 11.9% 1,503.6 1,101.9 36.5% Exceptional Items 0.0 0.0 - 0.0 - 0.0 0.0 - Profit before Tax 794.2 579.8 37.0% 709.4 11.9% 1,503.6 1,101.9 36.5% Tax expenses 199.4 147.0 35.7% 178.4 11.8% 377.9 283.2 33.4% Profit before Minority Interest 594.7 432.8 37.4% 531.0 12.0% 1,125.7 818.7 37.5% Minority Interest 0.0 0.0 - 0.0 - 0.0 0.0 - Profit after Tax (PAT) 594.7 432.8 37.4% 531.0 12.0% 1,125.7 818.7 37.5% PAT Margin (%) 23.3% 21.5% 181 bps 23.0% 30 bps 23.1% 21.0% 213 bps EPS – Basic (INR)* 5.8 4.2 37.2% 5.2 11.9% 10.9 8.0 37.4%
Page 10
10 Sustained Momentum Observed Across the Wellness Segment High Volume of Wellness testing being observed in younger population due to increased awareness & growing chronic disease burden due to stress, sedentary life & shift in lifestyle patterns Digital promotions by the organised players along with third party healthcare platforms have also aided in increased footfalls for wellness packages Adoption of wellness testing is scaling across markets, with Tier 2 and Tier 3 cities emerging as key growth drivers Faster report turnaround times (TAT), coupled with the convenience of home testing, have been key drivers of growth 1 4 3 2 27.1% 27.4% Q2 FY27 YOY Growth % H1 FY27 YOY Growth %
Page 11
Strategic Expansion Key Developments
Page 12
12 Launched State-of-the-Art Flagship Hub in JP Nagar, Bengaluru (1/2) Inaugurated State-of-the-Art Hub in JP Nagar in the 2nd week of July, 2026 in line with our strategy of expanding organically in Bengaluru 1 JP Nagar 10,000+ sq.ft. Hub houses advanced equipment like Wide Bore 3T MRI and Digital PET with 160 slice cardiac CT The Wide Bore 3T Omega MRI is first of its kind in Karnataka, offering significantly faster scan times while delivering enhanced patient comfort and a superior imaging experience
Page 13
13 Launched State-of-the-Art Flagship Hub in JP Nagar, Bengaluru (2/2) Inaugurated State-of-the-Art Hub in JP Nagar in the 2nd week of July, 2026 in line with our strategy of expanding organically in Bengaluru 1 JP Nagar 10,000+ sq.ft. Hub also houses full-fledged lab which will serve as the central lab for entire Bengaluru region Strategically located in the middle of several super-specialty hospitals
Page 14
14 Inaugurated 2 Spokes in Hyderabad (1/2)3 Inaugurated a spoke in Kothapet, Hyderabad in line with our strategy of building dense network and deepening marketing penetration
Page 15
15 Inaugurated 2 Spokes in Hyderabad (2/2)3 Inaugurated a spoke in Moghalpura, Hyderabad in line with our strategy of building dense network and deepening marketing penetration
Page 16
16 Strategic Foray into Assam with the Acquisition of Arya Wellness Centre4 The Seller is currently in the process of fulfilling the Conditions Precedent (CPs). We expect to commence operations under Vijaya from 1st January 2027 TRANSACTION CONSIDERATION ₹46.2 Cr. 8-9x FY26 Adjusted EBITDA (1) 1. IND AS EBITDA
Page 17
17 Expanding our Footprint with Entry into North-East Acquisition of Arya Wellness, provides Vijaya with an established operating platform in a strategically synergistic market, strengthening our Eastern India presence and creating a strong foundation for expansion across the North-East 6 States 7 States Synergistic Expansion Established Platform Existing Post Acquisition 4
Page 18
18 Leveraging the Transformative Power of AI for CT KUB Cases Reporting ▪ Auto-locates & measures stones ▪ Precise 3D localization of stones aids in anatomical orientation Automated Stone Detection & 3D Localization Incorporating AI has enhanced the surgical planning experience, and improves operational efficiency across the entire Urology pathway ▪ Prioritises urgent scans - flagging positive cases ▪ Cuts reporting time with precise volume & density data ▪ Reduces risk of missing small or faint stones Improving Radiologist’s Productivity & Accuracy ▪ Distinguishes true kidney stones from harmless pelvic vein calcifications and vascular spots in arteries Intelligent Differentiation ▪ Precise volume and density data helps in choosing the right intervention ▪ Accurate "stone burden" calculation allows for better prediction of stone-free rates after a single procedure Enhances Precision Surgical Planning for Urologist
Page 19
19 AI-Powered Dental Diagnostics for Precision Care ➢ AI dental diagnostics platform delivers high-precision 2D/3D radiograph analysis, predictive care, and clinical decision support ➢ Al-based 2D & CBCT scan analysis for faster, more accurate diagnostics ➢ Enhances patient outcomes & trust with visual decisions support ➢ Enables predictive care & personalized treatment planning
Page 20
Strategic Expansion Strategic Expansion
Page 21
21 Expanding Strategically in Alignment with our Vision East India Strategy Core Market Strategy Inorganic Expansion Strategy Expansion into Neighbouring State • Planning to add 3 hubs in FY27 to take our overall hub network to 6 hubs in Karnataka • Actively scouting for locations to add multiple hubs and spokes in FY28 and FY29 • Planning to add 1 Hub in the next 12 months to take our overall network to 8 in East India • Employing our proven hub and spoke model, aim to replicate our success in East India by creating a dense network • Successfully acquired PH, Pune's largest B2C integrated diagnostic chain • This strategic acquisition seamlessly aligns with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values • Operationalized 2 hubs in Ambegaon & Kalyani Nagar and 2 spokes under Vijaya PH Brand, following the acquisition • Planning to add 1-2 hubs in the next 12 months • Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles, strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed • Added a hub centre in Hyderabad in Q1 FY27 and planning to enter 2 key cities of AP - Vijayawada & Guntur & add multiple spokes across our core geography in the next 12 months Bengaluru AP Telangana Pune West Bengal Gurugram Kalaburagi
Page 22
22 Expansion Plans - Upcoming Hubs and Spokes Centres Geography Launched in H1 FY27 Upcoming Tentative Timelines for Commencement 1 Hub 4 Spokes 4 Spokes H2 FY27 2 Spokes 1 Hub 1 Spoke H2 FY27 H2 FY27 1 Hub 2 Hubs 1 Spoke H2 FY27 H2 FY27 - 1 Spoke H2 FY27 1 Spoke H1 FY27 2 Hubs 7 Spokes RoAPT Hyderabad Bengaluru West Bengal Pune H2 FY27 3 Hubs 7 Spokes Q1 FY28 3 Hubs - Spokes Mysore * In addition to the above expansion, we are planning to launch 3rd flagship centre in the western corridor of Hyderabad
Page 23
Strategic Expansion Company Overview
Page 24
24 Vijaya at a Glance Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 168 state-of-the-art centres spread across 27 cities & towns Founded by Mr. Surendranath Reddy in 1981 and currently led by Ms. Suprita Reddy 40+ Years of Vintage 400+ Doctors Radiologist & Pathologist network ~5.00 Mn Footfalls (1) Trusted by every Age group ~18.28 Mn Tests (1) Most preferred Diagnostic Centre 27 Cities and towns across India Largest B2C integrated Player in India Evolved from a regional player to a player with presence in multiple geographies … … While retaining its core values of providing Quality, Reliable & Accurate Diagnostic services at Affordable prices 168 Centres 18 labs with NABL Accreditation 1. Footfall and Tests for the 12 months ended 30-Sep-26
Page 25
25 Our Journey 1993 1995 2003 2005 2006 2008 2010 2013 2023 2019 2007 1981 ▪ Vijaya Diagnostic Centre incorporated in Hyderabad ▪ Became 1st independent diagnostic centre in South India to offer PET CT from Wipro GE Healthcare 2012 ▪ Recognized as one of the Best Imaging centres in Hyderabad by The Week 2016 ▪ Received investment from Karakoram Limited & Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF1 2018 ▪ Awarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership award ▪ Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group ▪ One of the earliest private diagnostic service providers to be approved for COVID RT- PCR testing by ICMR* 2021 ▪ Successfully listed on Indian Stock Exchanges (NSE* & BSE*) ▪ 1st independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare ▪ Successfully launched the first center in Kolkata under the "Vijaya“ brand name ▪ Acquired 100% stake in P.H. Diagnostics and forayed into Pune ▪ Awarded Best Brand at ET Edge Awards 2023 2024 ▪ Transitioned to AI Radiology Software - “Augmento” ▪ Awarded Icon in Integrated Diagnostic Services by Times Health Excellence ▪ Recognized as Fastest Growing Brands at Asian Business & Social Forum 2024, Dubai 2020 * ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange 2022 ▪ Awarded one of the Best Healthcare Brands 2022 by The Economic Times ▪ Won the Healthcare Leadership Awards 2022 ▪ Awarded Pride of India Brands Award – The Best of South Awards 2022 2025 ▪ Forayed into Bengaluru market by launching 2 hubs in Yelahanka and HSR Layout under the “Vijaya” brand name
Page 26
26 Integrated Diagnostics Player Offering One-Stop Solution Complete Range of Diagnostic Services under One Roof Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience Pathology (1) Radiology (1) 63.1 % 36.9 % 1. Revenue mix for Q2 FY27
Page 27
27 Dominant Position in Telangana & AP Markets with a Strong Brand Recall Hyderabad & Secunderabad Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets Vishakhapatnam Tirupati Nandyal Kurnool Ongole Nellore Nizamabad Rajahmundry Mancherial Mahabubnagar Karimnagar Hanamkonda Present in Key Geographies of AP & Telangana Hyderabad Revenue Contribution 67 (1) % RoAPT Revenue Contribution 20 (1) % A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests 1. For Q2 FY27 Bhuvanagiri Khammam AP Telangana Upcoming CentresExisting Centres VijayawadaGuntur Upcoming Centre in FY28
Page 28
28 Strong Traction observed in Newer Geographies (1/3) Differentiated offering has accelerated Vijaya’s success in new geographies Greater Kolkata Area Krishnanagar Diamond Harbour Faster break-even’s enable replication of densification strategy in newer geographies West Bengal Network Greater Kolkata Area Network West Bengal Existing Centres Upcoming Centres
Page 29
29 Strong Traction observed in Newer Geographies (2/3) Differentiated offering has accelerated Vijaya Brand’s success in new geographies Faster break-even’s enable replication of densification strategy in newer geographies Pune Network Pune Existing Centres Upcoming Centres
Page 30
30 Strong Traction observed in Newer Geographies (3/3) Differentiated offering has accelerated Vijaya Brand’s success in new geographies Faster break-even’s enable replication of densification strategy in newer geographies Bengaluru Network Bengaluru Kalaburagi Upcoming CentresExisting Centres Mysore
Page 31
31 Driving Geographical Diversification through Strategic Expansion Hyderabad RoAPT Pune West Bengal RoAPT - Rest of AP and Telangana Gurugram Kalaburagi 72%69% FY26 FY25 FY26 FY25 FY26 FY25 FY26 FY25 18%20% 6%6% 4% 6% Geographical Revenue Mix Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience 67% Q1 FY27 21% Q1 FY27 6% Q1 FY27 7% Q1 FY27 Bengaluru Q2 FY27 67% Q2 FY27 20% Q2 FY27 5% 8% Q2 FY27
Page 32
32 Boosting Accessibility with Best-in-class Online Services & Home Collections Home Collections Enhancing Customer Experience through Seamless Online App, E -Commerce Website and Call Centre Bookings Seamless & Efficient process High standards of hygiene maintained High Brand salience Access to reports online & historical medical records High customer stickiness Organic word of mouth growth Intuitive(1) & user-friendly interface Agile customer service team Elevating Customer Experience through Home Collections Temperature Controlled Logistics Reaches Lab within 2 hours (2) Online Services Pre-sealed & sterilized single-use home kit 2. Post Collection1. Patient can track his / her health trends over time
Page 33
33 Robust Technical Capabilities with State-of-the-art IT Infrastructure • Long standing relationship with medical technology vendors • At the forefront of introducing new tests by adopting the latest medical technologies • Among the first diagnostic service provider in South India to offer PET-CT scan in 2008 Key Suppliers Advanced Software to Manage Clinical Data Advance Laboratory Information Management System (LIMS) Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS) Front end IT infrastructure enabling… Standardization across our operations Reduce incidence of errors due to Low Human Intervention Monitor Technical Operations Closely track key performance metrics and maintain the Turn- Around Time (TAT) Provide Uniform Experience to customers from booking appointments to accessing reports online 41 CT Machines 10 PET CT / Gamma machines MRI Machines 44 Radiologists, Lab Doctors & Physicians 400+ NABL Accreditations 18 NABH Accreditations 10 Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipment in India which has helped in offering high quality services Note: Data above is as at 30-Sep-26
Page 34
34 Experienced Board of Directors Founder & Chairman Dr. S. Surendranath Reddy ✔ 40+ years of experience ✔ Holds Bachelor’s degree in Medicine and Doctor of Medicine in Radiology Managing Director & CEO Ms. Suprita Reddy ✔ 22+ years of experience ✔ Awarded Women Leadership Award in Healthcare by ABP Executive Director Mr. Sunil Chandra Kondapally ✔ 22+ years of experience ✔ Holds Bachelor’s degree in Electrical Engineering from Florida State University Non-Executive Director Ms. S Geeta Reddy ✔ 35+ years of experience ✔ BOD at Sura Agritech, Iffco Kisan, Namrata Diagnostics, etc. ✔ LLB from Osmania University Non-Executive Independent Director Mr. Dipinder Singh Sekhon ✔ 25+ years of experience ✔ Founder of AI Healthcare company iKites.ai ✔ MPA from LSE(1) ✔ BTech & MTech from IIT, Delhi Non-Executive Independent Director Mr. S. Murthy Chavali ✔ 35+ years of experience ✔ Ex-CEO - Aurigene Discovery Tech ✔ MBA from IIM, Bangalore & BTech from IIT, Madras Non-Executive Independent Director Mr. Ravi Shankararamiah ✔ 40+ years of experience and designated as Senior Advocate by High Court of Andhra Pradesh ✔ Graduated magna cum laude from USC, LA(2) in MS Non-Executive Independent Director Dr. Sasikala Paruchuri Kola ✔ 30+ years of experience as a Gynaecologist & Obstetrician ✔ Leadership roles in FOGSI (3) and OGSH(4) ✔ MD & DGO from Osmania Medical College 2. University of Southern California, Los Angeles 4. Obstetric and Gynaecological Society of Hyderabad3. Federation of Obstetric and Gynaecological Societies of India1. Master of Public Administration in Public & Economic Policy from London School of Economics
Page 35
35 Stellar Management Team Founder & Chairman Dr. S. Surendranath Reddy Managing Director & CEO Suprita Reddy Executive Director Sunil Chandra Kondapally Chief Operating Officer Sivaramaraju Vegesna, CFA Chief Financial Officer Narasimha Raju K.A Director - Laboratory Dr. Kiran B Director - Radiology Dr. V Vijayanand
Page 36
36 DIIs: Mutual Funds, AIFs and QIBs FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs Others: Retail, Bodies Corporate and others Shareholding Pattern as at 30th September, 2026 Shareholding Pattern as at 30th September, 2026 Key Investors Promoter & Promoter Group 52.5% DIIs 32.5% FIIs 10.7% Others 4.3%
Page 37
37 Doctors Connect Program in Q2 FY27
Page 38
38 Awards & Accolades Best Healthcare Brands’ 2024 recognized by ET Edge Best Brand awarded at ET Edge Awards 2023 Excellence In Comprehensive Diagnostic Care awarded by ABP Ananda Swasthya Samman Most Trusted Brand of India awarded by Marksmen Daily – 3rd edition Fastest Growing Leaders 2023- 24 awarded at Asian business & Social Forum 2024, Dubai Fastest Growing Brands 2023- 24 awarded at Asian business & Social Forum 2024, Dubai Most Preferred Workplace for Women 2024 – 25 recognized by Marksmen Daily Most Trusted Brand of India 2024-25 awarded by Marksmen Daily – 4th edition Best Healthcare Brands’ awarded by Economic Times - 2023 Best Healthcare Brands’ 2025 recognized by ET Edge Icon in Integrated Diagnostic Services by Times Health Excellence 2024 - TS & AP Icon in Integrated Diagnostic Services by Times Health Excellence TS & AP 2025 Best Diagnostic Centre awarded at HMTV Healthcare Awards 2025 Best Healthcare Brands 2026 recognized by ET Edge Most Preferred Workplace 2026-27 recognized by Marksmen Daily
Page 39
Strategic Expansion Annexure
Page 40
40 State-of-the-art Infrastructure (1/3)
Page 41
41 State-of-the-art Infrastructure (2/3)
Page 42
42 State-of-the-art Infrastructure (3/3)
Page 43
43 Advanced Equipment in Place to Deliver High Quality Services (1/2)
Page 44
44 Advanced Equipment in Place to Deliver High Quality Services (2/2)
Page 45
45 Robust Operational Metrics 2.57 3.17 3.35 3.53 3.62 FY22 FY23 FY24 FY25 FY26 Diagnostic Centre (Nos) Test per Footfall (Nos) 95 121 145 151 162 FY22 FY23 FY24 FY25 FY26 Footfalls (Mn) Revenue per Test (INR) 3.62 3.18 3.55 4.19 4.68 FY22 FY23 FY24 FY25 FY26 496 457 461 461 481 FY22 FY23 FY24 FY25 FY26 Tests Performed (Mn) Revenue per Footfall (INR) 9.32 10.05 11.89 14.79 16.92 FY22 FY23 FY24 FY25 FY26 1,276 1,446 1,543 1,627 1,740 FY22 FY23 FY24 FY25 FY26
Page 46
46 Consistent Financial Performance EBIDTA Margin (%) PAT Margin (%) Revenue 4,624 4,592 5,478 6,814 8,142 FY22 FY23 FY24 FY25 FY26 EBIDTA 2,037 1,820 2,209 2,732 3,369 FY22 FY23 FY24 FY25 FY26 PAT 1,097 846 1,188 1,438 1,730 FY22 FY23 FY24 FY25 FY26 44.1% 39.6% 40.3% 40.1% 41.4% FY22 FY23 FY24 FY25 FY26 23.7% 18.4% 21.7% 21.1% 21.2% FY22 FY23 FY24 FY25 FY26 (INR Mn) Integrated business model with high B2C concentration (~92%) and a strong brand recall has resulted in Industry leading margins Note: With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value (“WDV") method to Straight Line Method (“SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets. Due to the aforesaid change, the PAT for the year Financial year ended March 31, 2023 and Financial year ended March 31, 2024 was higher by Rs 67.7 Mn and Rs 290.8 Mn respectively Impact of COVID-19 Impact of COVID-19 Impact of COVID-19
Page 47
47 Sustainable Cash Generation & Increasing Return Ratios CFO (1) / EBIDTA (%) RoCE Pre-Tax (2) (%) RoE (3) (%) Surplus Cash (INR Mn) 1. CFO = Cash flow from Operations 2. ROCE (Pre-tax): (PBIT ex Other income) / (Average Networth + Average Long Term Lease Liabilities – Average Surplus Cash) 2,465 2,554 1,851 2,067 2,869 FY22 FY23 FY24 FY25 FY26 46% 26% 26% 25% 25% FY22 FY23 FY24 FY25 FY26 78% 90% 83% 82% 80% FY22 FY23 FY24 FY25 FY26 27% 17% 20% 20% 20% FY22 FY23 FY24 FY25 FY26 3. ROE: PAT / Average Networth
Page 48
48 Consolidated Profit & Loss Account (INR Mn) Particulars FY22 FY23 FY24 FY25 FY26 Revenue from operations 4,624 4,592 5,478 6,814 8,142 Cost of materials consumed 715 589 654 848 947 Employee benefits expense 707 785 902 1,122 1,307 Other expenses 1,165 1,398 1,712 2,113 2,518 EBITDA 2,037 1,820 2,209 2,732 3,369 EBITDA % 44.1% 39.6% 40.3% 40.1% 41.4% Other income 128 142 208 183 208 Depreciation and amortization expense 527 617 570 706 918 EBIT 1,638 1,344 1,847 2,209 2,659 Finance costs 165 209 240 267 332 Profit before tax and exceptional items 1,474 1,135 1,607 1,942 2,327 Exceptional items - - 21 10 - Profit before Tax 1,474 1,135 1,587 1,932 2,327 Tax expenses 367 283 390 494 597 Profit after Tax before Minority Interest 1,107 852 1,196 1,438 1,730 Minority Interest 10 5.8 8 - - Profit after Tax 1,097 846 1,188 1,438 1,730 PAT % 23.7% 18.4% 21.7% 21.1% 21.2% EPS – Basic (INR) 10.76 8.29 11.62 13.95 16.81
Page 49
49 Consolidated Balance Sheet (INR Mn) ASSETS Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 EQUITY & LIABILITIES Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 NON-CURRENT ASSETS 4,436 5,777 7,714 9,664 11,851 EQUITY 4,695 5,466 6,599 7,991 9,572 Property, plant and equipment 1,966 2,940 3,785 4,469 5,625 Equity share capital 102 102 102 103 103 Capital work-in-progress 341 271 83 703 343 Instruments entirely equity in nature - - - - - Goodwill 53 53 1,192 1,192 1,192 Other equity 4,593 5,364 6,497 7,889 9,469 Other intangible assets 14 22 207 219 204 Non-Controlling Interest Right of use asset 1,672 2,223 2,235 2,768 3,672 Intangible assets under development 1 6 5 0 8 NON-CURRENT LIABILITIES 1,778 2,406 2,500 3,119 4,260 Financial assets Financial liabilities - Investments 0 0 0 0 0 - Borrowings 0 0 0 0 0 - Other financial assets 75 90 113 165 481 - Lease liabilities 1,703 2,330 2,391 2,964 4,000 Deferred tax assets 89 83 29 0 0 - Other financial liabilities 0 0 0 0 0 Income tax assets 2 2 2 12 2 Provisions 74 71 106 99 110 Other assets 223 85 62 136 324 Other non current liabilities 1 5 3 3 5 Deferred tax liabilities - - - 53 145 CURRENT ASSETS 2,698 2,757 2,113 3,072 3,219 Inventories 43 20 52 49 49 CURRENT LIABILITIES 661 662 729 1,626 1,239 Financial assets Financial liabilities - Investments 542 1,390 1,091 1,846 2,284 - Borrowings 6 0 0 0 0 - Trade receivables 98 95 162 148 209 - Lease liabilities 126 145 201 232 226 - Cash and cash equivalents 110 242 222 128 397 - Trade payables 216 277 329 331 376 - Bank balances other than Cash and cash equivalents 1,813 922 508 361 131 - Other financial liabilities 248 140 114 925 491 - Loans 0 0 0 0 Income tax liabilities 9 24 12 35 9 - Other financial assets 51 36 31 478 80 Provisions 21 40 32 60 83 Other current assets 41 51 46 62 70 Other current liabilities 35 36 40 44 53 TOTAL ASSETS 7,135 8,534 9,828 12,736 15,070 TOTAL EQUITY AND LIABILITIES 7,135 8,534 9,828 12,736 15,070
Page 50
50 Consolidated Cash Flow Statement Surplus Cash *Current investments + investments with maturity more than 12 months (part of other non-current financial assets) Particulars Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 Cash Flow from Operating Activities Profit before Tax 1,474 1,135 1,587 1,932 2,327 Adjustment for Non-Operating Items 572 683 599 786 1,070 Operating Profit before Working Capital Changes 2,046 1,818 2,186 2,718 3,397 Changes in Working Capital -67 90 -14 -74 -168 Cash Generated from Operations 1,979 1,908 2,172 2,644 3,228 Less: Direct Taxes paid -399 -262 -339 -399 -522 Net Cash from Operating Activities 1,580 1,646 1,833 2,245 2,706 Purchase and construction of property, plant and building (net) -1,223 -1,248 -880 -955 -1,827 Acquisition of subsidiary - - -1,475 - - Investments (net) -127 734 530 -893 57 Others 120 887 401 29 28 Cash Flow from Investing Activities -1,231 -1,096 -1,423 -1,819 -1,742 Cash Flow from Financing Activities -306 -419 -445 -520 -695 Net increase/ (decrease) in Cash & Cash equivalent 44 131 -36 -94 269 Cash & Cash Equivalents at the beginning of the period 67 110 258 222 128 Cash & Cash equivalents at the end of the period 110 242 222 128 397 Particulars Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 Investments* 542 1,390 1,092 1,846 2,284 Cash and cash equivalents 110 242 222 128 397 Bank balances other than Cash and cash equivalents** 1,813 922 537 843 512 Less: Deferred Capital Creditors 750 323 Total 2,465 2,554 1,851 2,067 2,869 (INR Mn) ** Includes all the fixed deposits
Page 51
Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India. Mr. Dhiren Gala Head - Investor Relations & Corporate Development +91 90598 93206 dhiren.g@vijayadiagnostic.in ir@vijayadiagnostic.in www.vijayadiagnostic.com For further information please contact: Thank You